Hyperferritinemia and iron metabolism in Gaucher disease: Potential pathophysiological implications

Brady, 1965, Metabolism of glucocerebrosides. Evidence of an enzymatic deficiency in Gaucher's disease, Biochem Biophys Res Commun, 18, 221, 10.1016/0006-291X(65)90743-6 Grabowski, 2008, Phenotype, diagnosis, and treatment of Gaucher's disease, Lancet, 372, 1263, 10.1016/S0140-6736(08)61522-6 Charrow, 2000, The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease, Arch Intern Med, 160, 2835, 10.1001/archinte.160.18.2835 Cox, 1997, Gaucher's disease: clinical features and natural history, Baillieres Clin Haematol, 10, 657, 10.1016/S0950-3536(97)80033-9 Biegstraaten, 2011, A monozygotic twin pair with highly discordant Gaucher phenotypes, Blood Cells Mol Dis, 46, 39, 10.1016/j.bcmd.2010.10.007 Beutler, 2004, Enzyme replacement in Gaucher disease, PLoS Med, 1, 10.1371/journal.pmed.0010021 Cox, 2000, Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis, Lancet, 355, 1481, 10.1016/S0140-6736(00)02161-9 Lukina, 2014, Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4years of treatment, Blood Cells Mol Dis, 53, 274, 10.1016/j.bcmd.2014.04.002 Barton, 1991, Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher's disease, N Engl J Med, 324, 1464, 10.1056/NEJM199105233242104 Weinreb, 2013, Long-term clinical outcomes in type 1 Gaucher disease following 10years of imiglucerase treatment, J Inherit Metab Dis, 36, 543, 10.1007/s10545-012-9528-4 van Dussen, 2014, Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications, Orphanet J Rare Dis, 9, 112, 10.1186/s13023-014-0112-x Langeveld, 2008, Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance, J Clin Endocrinol Metab, 93, 845, 10.1210/jc.2007-1702 Taddei, 2010, High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease, J Inherit Metab Dis, 33, 291, 10.1007/s10545-010-9070-1 Sidransky, 2009, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease, N Engl J Med, 361, 1651, 10.1056/NEJMoa0901281 Biegstraaten, 2010, Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study, Brain, 133, 2909, 10.1093/brain/awq198 Arends, 2013, Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature, Br J Haematol, 161, 832, 10.1111/bjh.12335 Weinreb, 2013, Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy, Crit Rev Oncog, 18, 177, 10.1615/CritRevOncog.2013005921 de Fost, 2006, Increased incidence of cancer in adult Gaucher disease in Western Europe, Blood Cells Mol Dis, 36, 53, 10.1016/j.bcmd.2005.08.004 Taddei, 2009, The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients, Am J Hematol, 84, 208, 10.1002/ajh.21362 Xu, 2005, Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature, Semin Liver Dis, 25, 226, 10.1055/s-2005-871201 Pantopoulos, 2012, Mechanisms of mammalian iron homeostasis, Biochemistry, 51, 5705, 10.1021/bi300752r Kell, 2010, Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples, Arch Toxicol, 84, 825, 10.1007/s00204-010-0577-x De Domenico, 2008, Regulation of iron acquisition and storage: consequences for iron-linked disorders, Nat Rev Mol Cell Biol, 9, 72, 10.1038/nrm2295 Mekinian, 2012, Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment, Blood Cells Mol Dis, 49, 53, 10.1016/j.bcmd.2012.04.002 Stein, 2010, Hyperferritinemia and iron overload in type 1 Gaucher disease, Am J Hematol, 85, 472, 10.1002/ajh.21721 Finch, 1986, Plasma ferritin determination as a diagnostic tool, West J Med, 145, 657 Wang, 1800, Serum ferritin: past, present and future, Biochim Biophys Acta, 2010, 760 Drakesmith, 2015, Ironing out ferroportin, Cell Metab, 22, 777, 10.1016/j.cmet.2015.09.006 Ramm, 2005, Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis, Semin Liver Dis, 25, 433, 10.1055/s-2005-923315 Grabowski, 2010, Gaucher disease Lorber, 1960, The occurrence of intracellular iron in Gaucher's disease, Ann Intern Med, 53, 293, 10.7326/0003-4819-53-2-293 Lee, 1967, Gaucher's disease. A morphologic study and measurements of iron metabolism, Am J Med, 42, 891, 10.1016/0002-9343(67)90070-8 Lorber, 1967, Identification of ferritin within gaucher cells. An electron microscopic and immunofluorescent study, Acta Haematol, 37, 189, 10.1159/000209069 Lorber, 1970, Adult type Gaucher's disease: a secondary disorder of iron metabolism, Mt Sinai J Med, 37, 404 Amato, 2013, To the editor: resolution of thrombocytopenia with JAK2 mutation in a patient with Gaucher disease, Blood, 122, 4287, 10.1182/blood-2013-08-524447 Mandlebaum, 1912, A contribution to the pathology of primary splenomegaly (Gaucher type), with the report of an autopsy on a male child four and one half years of age, J Exp Med, 16, 797, 10.1084/jem.16.6.797 Sood, 1971, Gaucher's disease in mother and daughter, Br Med J, 1, 590, 10.1136/bmj.1.5749.590 Weisberger, 2004, Cytochemical diagnosis of Gaucher's disease by iron stain, Br J Haematol, 124, 696, 10.1046/j.1365-2141.2003.04695.x Zhou, 2013, Novel G377S (c.1246G>T) mutation associated with Gaucher disease type 1, Am J Hematol., 88, 922, 10.1002/ajh.23537 Bogoeva, 2001, Immunohistochemical and ultrastructural features of Gaucher's cells—five case reports, Acta Med Croatica, 55, 131 Sharma, 2000, Perinatal lethal form of Gaucher's disease presenting with hemosiderosis, Am J Perinatol, 17, 201, 10.1055/s-2000-9419 Iancu, 1996, The application of laser microprobe mass analysis to the study of biological material, Biometals, 9, 57, 10.1007/BF00188091 Zimran, 1992, Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients, Medicine, 71, 337, 10.1097/00005792-199211000-00002 Aerts, 1997, Plasma and metabolic abnormalities in Gaucher's disease, Baillieres Clin Haematol, 10, 691, 10.1016/S0950-3536(97)80034-0 Morgan, 1983, Serum ferritin concentration in Gaucher's disease, Br Med J, 286, 1864, 10.1136/bmj.286.6381.1864 Decaux, 2003, Hyperferritinemia revealing Gaucher's disease, Eur J Intern Med, 14, 199, 10.1016/S0953-6205(03)00038-4 Sumarac, 2011, Biomarkers in Serbian patients with Gaucher disease, Clin Biochem, 44, 950, 10.1016/j.clinbiochem.2011.05.016 Arosio, 1790, Ferritins: a family of molecules for iron storage, antioxidation and more, Biochim Biophys Acta, 2009, 589 Theil, 2003, Ferritin: at the crossroads of iron and oxygen metabolism, J Nutr, 133, 1549S, 10.1093/jn/133.5.1549S Cohen, 2010, Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway, Blood, 116, 1574, 10.1182/blood-2009-11-253815 Hentze, 2010, Two to tango: regulation of mammalian iron metabolism, Cell, 142, 24, 10.1016/j.cell.2010.06.028 Fautrel, 2002, Ferritin levels in adult Still's disease: any sugar?, Joint Bone Spine, 69, 355, 10.1016/S1297-319X(02)00409-8 Fautrel, 2001, Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease, J Rheumatol, 28, 322 Stirnemann, 2011, Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease, Blood Cells Mol Dis, 46, 34, 10.1016/j.bcmd.2010.10.014 Rosario, 2013, The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome, BMC Med, 11, 185, 10.1186/1741-7015-11-185 Allen, 1997, Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10, QJM, 90, 19, 10.1093/qjmed/90.1.19 van Breemen, 1772, Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease, Biochim Biophys Acta, 2007, 788 Nemeth, 2004, IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin, J Clin Invest, 113, 1271, 10.1172/JCI200420945 Mizukami, 2002, Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage, J Clin Invest, 109, 1215, 10.1172/JCI0214530 Medrano-Engay, 2014, Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease, Blood Cells Mol Dis, 53, 171, 10.1016/j.bcmd.2014.07.007 Schafer, 2000, Acidic pH amplifies iron-mediated lipid peroxidation in cells, Free Radic Biol Med, 28, 1175, 10.1016/S0891-5849(00)00319-1 Kurz, 2008, Lysosomes in iron metabolism, ageing and apoptosis, Histochem Cell Biol, 129, 389, 10.1007/s00418-008-0394-y Kurz, 2011, The role of lysosomes in iron metabolism and recycling, Int J Biochem Cell Biol, 43, 1686, 10.1016/j.biocel.2011.08.016 Kurz, 1780, Lysosomes and oxidative stress in aging and apoptosis, Biochim Biophys Acta, 2008, 1291 Kidane, 2006, Release of iron from ferritin requires lysosomal activity, Am J Physiol Cell Physiol, 291, C445, 10.1152/ajpcell.00505.2005 Mancias, 2014, Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy, Nature, 509, 105, 10.1038/nature13148 Cabantchik, 2014, Labile iron in cells and body fluids: physiology, pathology, and pharmacology, Front Pharmacol, 5, 45, 10.3389/fphar.2014.00045 Brissot, 1820, Non-transferrin bound iron: a key role in iron overload and iron toxicity, Biochim Biophys Acta, 2012, 403 de Swart, 2016, Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders, Haematologica, 101, 38, 10.3324/haematol.2015.133983 Zimran, 2005, Survey of hematological aspects of Gaucher disease, Hematol (Amsterdam, Neth), 10, 151 Krasnewich, 1998, Splenectomy in Gaucher disease: new management dilemmas, Blood, 91, 3085 Weinreb, 2002, Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the gaucher registry, Am J Med, 113, 112, 10.1016/S0002-9343(02)01150-6 Bratosin, 2011, A cytometric study of the red blood cells in Gaucher disease reveals their abnormal shape that may be involved in increased erythrophagocytosis, Cytometry B Clin Cytom, 80, 28, 10.1002/cyto.b.20539 Boven, 2004, Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages, Am J Clin Pathol, 122, 359, 10.1309/BG5VA8JRDQH1M7HN Recalcati, 2010, Differential regulation of iron homeostasis during human macrophage polarized activation, Eur J Immunol, 40, 824, 10.1002/eji.200939889 Schmidt, 2015, Regulation of iron metabolism by hepcidin under conditions of inflammation, J Biol Chem, 290, 18975, 10.1074/jbc.R115.650150 Wu, 2013, GDF15-mediated upregulation of ferroportin plays a key role in the development of hyperferritinemia in children with hemophagocytic lymphohistiocytosis, Pediatr Blood Cancer, 60, 940, 10.1002/pbc.24373 Kautz, 2014, Molecular liaisons between erythropoiesis and iron metabolism, Blood, 124, 479, 10.1182/blood-2014-05-516252 Kautz, 2015, Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia, Blood, 126, 2031, 10.1182/blood-2015-07-658419 Funke, 2013, Genetics and iron in the systems biology of Parkinson's disease and some related disorders, Neurochem Int, 62, 637, 10.1016/j.neuint.2012.11.015 Mistry, 2013, Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism, Crit Rev Oncog, 18, 235, 10.1615/CritRevOncog.2013006145 Kowdley, 2004, Iron, hemochromatosis, and hepatocellular carcinoma, Gastroenterology, 127, S79, 10.1016/j.gastro.2004.09.019 Bassan, 1985, Interaction between a serum factor and T lymphocytes in Gaucher disease, Am J Hematol, 18, 381, 10.1002/ajh.2830180407 Fernandez-Real, 2002, Cross-talk between iron metabolism and diabetes, Diabetes, 51, 2348, 10.2337/diabetes.51.8.2348 Davis, 1986, Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane, J Biol Chem, 261, 8708, 10.1016/S0021-9258(19)84438-1 Niederau, 1984, Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation?, Diabetologia, 26, 441, 10.1007/BF00262217 Bertelsen, 2001, Oxidative stress impairs insulin internalization in endothelial cells in vitro, Diabetologia, 44, 605, 10.1007/s001250051667 Ganz, 2009, Iron sequestration and anemia of inflammation, Semin Hematol, 46, 387, 10.1053/j.seminhematol.2009.06.001 Weinstein, 2002, Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease, Blood, 100, 3776, 10.1182/blood-2002-04-1260